Please provide your email address to receive an email when new articles are posted on . Subcutaneous infliximab outperformed placebo across disease locations in Crohn’s disease, even in the terminal ...
Switching between infliximab biosimilar SB2 and the reference product did not affect clinical disease activity or safety in IBD patients. No significant changes were observed in clinical outcomes, ...
BERLIN — Ulcerative colitis (UC) patients who fail on first-line therapy appear to have better outcomes with vedolizumab (Entyvio) than with infliximab, suggests EFFICACI, the first trial directly ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback